Biogen SEC filings, summarized
We read every Biogen 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track BIIB in your inbox
Add Biogen to your watchlist — free, every morning.
Recent filings
Biogen ($BIIB) announced Chief Legal Officer Susan H.
Biogen ($BIIB) announced Chief Legal Officer Susan H. Alexander will depart effective end of May 2026; 8‑K filed Mar 11, 2026. ⚖️📄 #Biogen #SEC The company…
Biogen ($BIIB) Board elected Dr.
Biogen ($BIIB) Board elected Dr. Maria C. Friere as Chair of the Board on Feb 11, 2026; her term as Chair is effective after the company’s Annual Meeting.…
Feb 11, 2026 — Biogen Board Chair Caroline Dorsa announced she will not stand for re‑election at the 2026…
Feb 11, 2026 — Biogen Board Chair Caroline Dorsa announced she will not stand for re‑election at the 2026 Annual Meeting of Stockholders. Company says…
Biogen ($BIIB) filed a Form 8‑K on Feb 6, 2026 furnishing a press release dated Feb 6, 2026 (Exhibit 99.1)…
Biogen ($BIIB) filed a Form 8‑K on Feb 6, 2026 furnishing a press release dated Feb 6, 2026 (Exhibit 99.1) and the Cover Page Inline XBRL file (Exhibit…
Biogen ($BIIB) on Feb 6, 2026 issued a press release announcing results of operations & financial…
Biogen ($BIIB) on Feb 6, 2026 issued a press release announcing results of operations & financial condition for Q4 and FY ended Dec 31, 2025. Press release…
Biogen expects a ~$222M pre-tax acquired IPR&D/upfront & milestone charge in Q4 2025, cutting GAAP and…
Biogen expects a ~$222M pre-tax acquired IPR&D/upfront & milestone charge in Q4 2025, cutting GAAP and non‑GAAP diluted EPS by ~$1.26 for the quarter.…